April 24, 2018 / 12:49 PM / 5 months ago

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

April 24 (Reuters) - Nektar Therapeutics:

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

* NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL EACH MAINTAIN GLOBAL COMMERCIAL RIGHTS TO THEIR RESPECTIVE INVESTIGATIONAL MEDICINES

* NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL SPLIT COSTS RELATED TO CLINICAL TRIAL

* NEKTAR THERAPEUTICS - FIRST TRIAL IS EXPECTED TO START IN SECOND HALF OF 2018

* NEKTAR - FIRST TRIAL TO EVALUATE COMBINATION OF EVERY 3-WEEK SCHEDULE OF NKTR-214 WITH ORAL DAILY DOSES OF TAK-659 IN PATIENTS WITH NON-HODGKIN LYMPHOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below